Modulaton of stress analgesia with tetrahydrocannabinol or cannabidiol

Modulaton of stress analgesia with tetrahydrocannabinol or cannabidiol - LOGIN-TS4

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00005442

Enrollment

Registered

2013-11-28

Start date

2014-02-07

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

healthy volunteers

Interventions

Group 1: 10 mg Tetrahydrocannabinol as oral capsule Group 2: 600 mg Cannabidiol as oral capsule Group 3: Placebo capsule

Eligibility

Sex/Gender

Male

Age

18 Years to 50 Years

Inclusion criteria

Inclusion criteria: age 18-50 years, right handed, male

Exclusion criteria

Exclusion criteria: Cannabis use on life span > 5 times, other substance dependencies (except nicotine), other axis I disorders, epilepsy, chronic diseases (such as diabetes mellitus), hypersensitivity reactions, other diseases that are incompatible with the planned study procedure.

Design outcomes

Primary

Measure	Time frame
fMRI signal dependent on drug measured during stress analgesia	—

Secondary

Measure	Time frame
subjective Painrating (Likert Scale 1-10, Manikin-Scale according to Bradley)	—

Countries

Germany

Contacts

Public ContactMartin Löffler

ZI Mannheim

martin.loeffler@zi-mannheim.de0621 1703 6349

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026